James F. Lymp
Bristol-Myers Squibb (United States) · 70 works · 10,267 citations · h-index 38
Top works
- The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
- Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
- Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains
- Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation*
- Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
- Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma
- Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease
- The Hospital Mortality of Patients Admitted to the ICU on Weekends
- Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non‐alcoholic fatty liver disease
- Improved Specificity of Newborn Screening for Congenital Adrenal Hyperplasia by Second-Tier Steroid Profiling Using Tandem Mass Spectrometry
- Chronological development of elevated aminotransferases in a nonalcoholic population
- The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis
- Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study
- Survey Assessment of Personal Digital Assistant Use among Trainees and Attending Physicians
- Acute lung injury after blood transfusion in mechanically ventilated patients
- Steroid Profiling by Tandem Mass Spectrometry Improves the Positive Predictive Value of Newborn Screening for Congenital Adrenal Hyperplasia
- Mortality rate and length of stay of patients admitted to the intensive care unit in July*
- Familial Idiopathic Pulmonary Fibrosis
- Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
- Reduction in apolipoprotein-mediated removal of cellular lipids by immortalization of human fibroblasts and its reversion by cAMP: lack of effect with Tangier disease cells